Susoctocog alfa - Shire

Drug Profile

Susoctocog alfa - Shire

Alternative Names: B-Domain deleted recombinant porcine factor VIII (OBI-1); BAX 802; BAX801; Factor VIII - Ipsen; FVIII - Ipsen; OBI-1; Obizur; PFVIII; Porcine FVIII; Recombinant porcine factor VIII - Inspiration/Ipsen; RpfVIII; SHP672

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Emory University
  • Developer Baxalta; Shire
  • Class Antihaemorrhagics; Blood coagulation factors; Recombinant proteins
  • Mechanism of Action Factor VII stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia A
  • New Molecular Entity No

Highest Development Phases

  • Marketed Haemophilia A

Most Recent Events

  • 24 Jun 2016 Baxalta plans a phase III trial for Haemophilia A in United Kingdom (UKCRN30415)
  • 15 Jun 2016 Baxalta initiates enrolment in a phase III trial for Haemophilia A in Spain (EudraCT2015-005521-39)
  • 03 Jun 2016 Baxalta has been acquired and merged into Shire
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top